By Fineline Cube Huadong Medicine Co., Ltd (SHE: 000963) announced that HDM2024, a Category 1 innovative bispecific antibody-drug conjugate (Bs-ADC), has received FDA clearance to initiate a Phase I clinical trial for the treatment of advanced solid tumors. The first-in-class candidate simultaneously targets EGFR (HER1) and HER3, delivering a DNA topoisomerase I inhibitor payload via a cleavable linker to block proliferative signaling while exerting direct cytotoxic antitumor effects. Preclinical data demonstrate potent activity across diverse target expression levels with favorable druggability and safety profiles, positioning Huadong Medicine to enter the competitive EGFR/HER3-targeted oncology space with a differentiated bispecific ADC platform.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | U.S. Food and Drug Administration (FDA) |
| Approval Type | IND clearance – Phase I |
| Product | HDM2024 |
| Drug Class | Bispecific antibody-drug conjugate (Bs-ADC) – Category 1 innovative biological drug |
| Targets | EGFR (HER1) + HER3 (bispecific antibody) |
| Payload | DNA topoisomerase I inhibitor |
| Linker | Cleavable |
| Indication | Advanced solid tumors |
| Developer | Huadong Medicine Co., Ltd (SHE: 000963) |
| Approval Date | 12 Mar 2026 |
Drug Profile & Mechanism
| Attribute | HDM2024 Specification |
|---|---|
| Architecture | Bispecific antibody (anti-EGFR/anti-HER3) + cleavable linker + topoisomerase I inhibitor payload |
| Dual Targeting | Simultaneous EGFR and HER3 blockade |
| Mechanism of Action | • Signal Interruption: Blocks EGFR/HER3-mediated proliferative signaling • Payload Delivery: Releases cytotoxic topoisomerase I inhibitor into tumor cells • Synergistic Effect: Combined receptor blockade + DNA damage |
| Payload Class | DNA topoisomerase I inhibitor (camptothecin derivative class) |
| Preclinical Activity | Potent antitumor efficacy across various solid tumor models with different target expression levels |
| Developability | Favorable manufacturing and safety profiles |
Scientific Rationale:
- EGFR/HER3 Co-expression: Common in lung, colorectal, head/neck, and pancreatic cancers; HER3 activation drives resistance to EGFR monotherapy
- Bispecific Advantage: Dual blockade prevents compensatory signaling; enhanced tumor specificity via avidity effects
- ADC Enhancement: Cytotoxic payload addresses heterogeneous target expression; bystander effect on neighboring cells
Strategic Context & Market Opportunity
| Factor | Implication |
|---|---|
| EGFR/HER3 Market | Established validation (cetuximab, panitumumab for EGFR; patritumab deruxtecan HER3 ADC in Phase III); HDM2024 offers differentiated bispecific approach |
| Resistance Challenge | EGFR monotherapy resistance via HER3 upregulation; HDM2024 bispecific design addresses escape mechanism |
| China Innovation | Huadong Medicine (traditional pharma) pivots to biologics innovation; FDA approval validates global R&D capabilities |
| Solid Tumor Breadth | EGFR/HER3 expression across multiple indications enables basket trial design; biomarker-driven patient selection |
| Competitive Timing | First-in-class bispecific ADC window; patent estate protection for novel format |
Competitive Landscape
| Competitor | Product | Mechanism | Status | HDM2024 Differentiation |
|---|---|---|---|---|
| Daiichi Sankyo | Patritumab deruxtecan (HER3-DXd) | HER3 ADC | Phase III (lung cancer) | Bispecific EGFR/HER3 targeting vs. HER3 alone; dual signal blockade |
| Amgen | Symphogen (EGFR/HER3 bsAb, no ADC) | Bispecific antibody (naked) | Phase I | HDM2024 adds cytotoxic payload for enhanced efficacy |
| AstraZeneca | Tagrisso (osimertinib) | EGFR TKI | Approved (EGFRm NSCLC) | ADC mechanism vs. kinase inhibition; different resistance profile |
| Huadong Medicine | HDM2024 | EGFR/HER3 Bs-ADC | Phase I-ready | First bispecific ADC targeting both receptors; dual mechanism |
Development Outlook
| Phase | Timeline | Objectives |
|---|---|---|
| Phase I | 2026-2027 | Safety, tolerability, MTD; pharmacokinetics; preliminary efficacy in EGFR/HER3-positive solid tumors |
| Expansion Cohorts | 2027-2028 | NSCLC, colorectal, head/neck cancer; biomarker stratification |
| Phase II | 2028-2030 | Registrational efficacy signals; combination with checkpoint inhibitors |
| Global Strategy | 2027+ | China NMPA IND; EU EMA filing; partnership discussions for ex-China commercialization |
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, first-in-class positioning, and competitive differentiation for HDM2024. Actual results may differ due to novelty of bispecific ADC format, manufacturing complexity, and competitive dynamics in the EGFR/HER3-targeted oncology market.-Fineline Info & Tech